---
title: "Anteris Grants 20,000 Unquoted RSUs Under Employee Incentive Plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282631122.md"
description: "Anteris Technologies Global Corp. has granted 20,000 unquoted restricted stock units (RSUs) under its employee incentive plan, divided into two tranches of 10,000 units each, issued on April 10 and April 13, 2026. This move aims to attract and retain talent by aligning employee interests with long-term shareholder value. The RSUs reflect the company's strategy of using equity-based compensation to support its growth in the competitive cardiovascular technology market. The latest analyst rating for Anteris Technologies (AU:AVR) is a Buy, with a price target of A$13.00."
datetime: "2026-04-14T04:58:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282631122.md)
  - [en](https://longbridge.com/en/news/282631122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282631122.md)
---

# Anteris Grants 20,000 Unquoted RSUs Under Employee Incentive Plan

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Anteris Technologies ( (AU:AVR) ).

Anteris Technologies Global Corp. has issued a total of 20,000 unquoted restricted stock units (RSUs) under its employee incentive scheme, allocated in two equal tranches of 10,000 units on April 10 and April 13, 2026. The new RSUs, which will not be quoted on the ASX, underscore the company’s continued use of equity-based compensation to attract and retain key talent, aligning employee interests with long-term shareholder value.

The issuance of these unquoted incentives reflects Anteris’s ongoing reliance on share-based remuneration as it advances its cardiovascular technology portfolio in competitive global markets. While modest in size, the award further embeds performance-linked ownership among staff, which may support execution of the company’s growth strategy without immediate cash outlay or dilution in the quoted market.

The most recent analyst rating on (AU:AVR) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Anteris Technologies stock, see the AU:AVR Stock Forecast page.

**More about Anteris Technologies**

Anteris Technologies Global Corp., listed on the ASX under the code AVR, operates in the medical technology sector, focusing on developing and commercializing innovative cardiovascular solutions. The company targets global healthcare markets with products designed to address structural heart disease and improve patient outcomes.

**Average Trading Volume:** 17,646

**Technical Sentiment Signal:** Sell

Find detailed analytics on AVR stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [AVR.US](https://longbridge.com/en/quote/AVR.US.md)

## Related News & Research

- [L1 Capital Pty Ltd Sells 558,633 Shares of Anteris Technologies Global (NASDAQ:AVR) Stock](https://longbridge.com/en/news/294503402.md)
- [L1 Capital reports $5.85 million Anteris Technologies common share disposal](https://longbridge.com/en/news/294497274.md)
- [Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Sells 208,731 Shares](https://longbridge.com/en/news/294196889.md)
- [Major Investor Move Shakes Up Anteris Technologies Global Corp. Stock](https://longbridge.com/en/news/294149763.md)
- [High Roller Technologies, Inc. (NYSEAMERICAN:ROLR) Short Interest Update](https://longbridge.com/en/news/294425462.md)